Company intelligence / Profile preview

ImperiaStone

Nigeria

Ownership: Private
Development stage: Other

Overview

ImperiaStone, Ltd. is a Nigerian-based company that historically focused on commodities, energy, and infrastructure before expanding into the pharmaceutical sector. In 2017, the company entered into a strategic partnership with Immune Therapeutics, Inc. to distribute Lodonal, a low-dose naltrexone therapy, within the Nigerian market. ImperiaStone specifically targets large-scale organizations, such as those in the mining industry, to provide healthcare solutions for employees. The company's leadership consists of professionals with diverse business backgrounds committed to diversifying the Nigerian economy through high-impact healthcare partnerships.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Non-Academic Healthcare

Partnerships

Immune Therapeutics

Beyond the preview

Go deeper on ImperiaStone.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImperiaStone.

Explore the full profile